Previous studies have observed that Kv10.2, which is overexpressed in renal cell carcinoma, melanoma, pancreatic cancer, and medulloblastoma, can be a potential target for cancer therapy. This evidence concerns the gene KCNH5 and pancreatic neoplasm.